CANCER BIOPHYSICS AND MECHANOBIOLOGY IN SILICO MULTISCALE MODELLING

TRACK NUMBER 400

VASILEIOS VAVOURAKIS^{1,2}, ALFONSO CAIAZZO³, HECTOR GOMEZ⁴, MIGUEL O. BERNABEU⁵, REBECCA SHIPLEY⁶, MARK CHAPLAIN⁷ AND RALPH SINKUS⁸

¹ Mechanical & Manufacturing Engineering Dept., University of Cyprus, Cyprus – vasvav@ucy.ac.cy
² Medical Physics & Biomedical Engineering Dept., University College London, UK

Key words: Personalized Models, Tumor-Host Microenvironment, Cancer Therapy.

ABSTRACT

To understand and, thus, treat cancer, experts in the field employ sophisticated *in vitro* and *in vivo* modelling approaches. Such systems have permitted investigators elucidate tumor pathophysiology, including genetic and biochemical mechanisms of cancer. Moreover, *in vitro* and *in vivo* models are extensively used for cancer-drug testing purposes. However, despite the progress made, it is becoming evident that targeted, reliable and successful treatment of cancer necessitates an integrative, multiscale, cancer-biology system approach. To address this, *in silico* models have emerged and have proven a very powerful tool to study and understand cancer development, the complexity and heterogeneity of its microenvironment, the transport of anti-cancer drugs and the effects of radiotherapy.

The purpose of this minisymposium is to act as a forum for presenting the *state of the art* mathematical and computational modelling approaches and techniques in the field of cancer biophysics, mechanobiology, and in cancer therapy modelling. Therefore, in this minisymposium, we aim to foster the exchange of knowledge and ideas in cancer research between engineers, physicists, mathematicians, tissue engineers, biologists and clinicians. We solicit contributions addressing challenges related to mathematical and computational modelling in cancer research, with particular emphasis in:

- multiscale modelling methods: from tissue to cell, to protein and molecular levels;
- challenges related to numerical methods for single-scale or/and multiscale cancer models:
- in silico simulations integrated with in vitro or/and in vivo laboratory experiments;
- coupled imaging and numerical modelling techniques;
- drug delivery, *in silico* drug testing, and nanomedicine modelling procedures;
- personalized models in cancer chemotherapy or/and radiotherapy.

 $^{^3}$ Weierstrass Institute for Applied Analysis & Stochastics, Germany – $\underline{caiazzo@wias\text{-berlin.de}}$

⁴ School of Mechanics Engineering, Purdue University, USA – <u>hectorgomez@purdue.edu</u>

⁵ Centre for Medical Informatics, The University of Edinburgh, UK – miguel.bernabeu@ed.ac.uk

⁶ Mechanical Engineering Dept., University College London, UK – <u>rebecca.shipley@ucl.ac.uk</u>

⁷ School of Mathematics and Statistics, University of St Andrews, UK – <u>majc@st-andrews.ac.uk</u>

⁸ National Institute of Health and Medical Research, France – <u>ralph.sinkus@inserm.fr</u>